Search Results - "Boyer, Michael J"

Mitochondrial Fission Mediates Endothelial Inflammation by Forrester, Steven J., Preston, Kyle J., Cooper, Hannah A., Boyer, Michael J., Escoto, Kathleen M., Poltronetti, Anthony J., Elliott, Katherine J., Kuroda, Ryohei, Miyao, Masashi, Sesaki, Hiromi, Akiyama, Tomoko, Kimura, Yayoi, Rizzo, Victor, Scalia, Rosario, Eguchi, Satoru

“…Endothelial inflammation and mitochondrial dysfunction have been implicated in cardiovascular diseases, yet, a unifying mechanism tying them together remains…”
Get full text

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma by Kao, Steven C, Cheng, Yuen Yee, Williams, Marissa, Kirschner, Michaela B, Madore, Jason, Lum, Trina, Sarun, Kadir H, Linton, Anthony, McCaughan, Brian, Klebe, Sonja, van Zandwijk, Nico, Scolyer, Richard A, Boyer, Michael J, Cooper, Wendy A, Reid, Glen

“…The upregulation of programmed death ligand 1 (PD-L1) is found in many cancers and contributes to evasion of the host's immune defense. In malignant pleural…”
Get more information

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy by KAO, Steven C. H, PAVLAKIS, Nick, HARVIE, Rozelle, VARDY, Janette L, BOYER, Michael J, VAN ZANDWIJK, Nico, CLARKE, Stephen J

“…Asbestos-induced chronic inflammation is implicated in the pathogenesis of malignant mesothelioma (MM). We have investigated blood neutrophil-to-lymphocyte…”
Get full text

Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials by YU YANG SOON, STOCKLER, Martin R, ASKIE, Lisa M, BOYER, Michael J

“…To determine if it is preferable to extend chemotherapy beyond a standard number of cycles in patients receiving first-line chemotherapy for advanced…”
Get full text

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial by Ramalingam, Suresh S, Prof, Jänne, Pasi A, Prof, Mok, Tony, Prof, O'Byrne, Kenneth, Prof, Boyer, Michael J, Prof, Von Pawel, Joachim, Prof, Pluzanski, Adam, MD, Shtivelband, Mikhail, MD, Docampo, Lara Iglesias, MD, Bennouna, Jaafar, MD, Zhang, Hui, PhD, Liang, Jane Q, PhD, Doherty, Jim P, PhD, Taylor, Ian, PhD, Mather, Cecile B, MS, Goldberg, Zelanna, MD, O'Connell, Joseph, MD, Paz-Ares, Luis, Prof

“…Summary Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a phase 2 study in non-small cell lung cancer showed…”
Get full text

Caveolin-1 Deletion Prevents Hypertensive Vascular Remodeling Induced by Angiotensin II by Forrester, Steven J, Elliott, Katherine J, Kawai, Tatsuo, Obama, Takashi, Boyer, Michael J, Preston, Kyle J, Yan, Zhen, Eguchi, Satoru, Rizzo, Victor

“…It has been proposed that membrane microdomains, caveolae, in vascular cells are critical for signal transduction and downstream functions induced by…”
Get full text

Involvement of Senescence and Mitochondrial Fission in Endothelial Cell Pro-Inflammatory Phenotype Induced by Angiotensin II by Miyao, Masashi, Cicalese, Stephanie, Kawai, Tatsuo, Cooper, Hannah A, Boyer, Michael J, Elliott, Katherine J, Forrester, Steven J, Kuroda, Ryohei, Rizzo, Victor, Hashimoto, Tomoki, Scalia, Rosario, Eguchi, Satoru

“…Angiotensin II (AngII) has a crucial role in cardiovascular pathologies, including endothelial inflammation and premature vascular aging. However, the precise…”
Get full text

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer by Mok, Tony S K, Wu, Yi-Long, Yu, Chong-Jen, Zhou, Caicun, Chen, Yuh-Min, Zhang, Li, Ignacio, Jorge, Liao, Meilin, Srimuninnimit, Vichien, Boyer, Michael J, Chua-Tan, Marina, Sriuranpong, Virote, Sudoyo, Aru W, Jin, Kate, Johnston, Michael, Chui, Winsome, Lee, Jin-Soo

“…This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected,…”
Get full text

Endothelial cell-derived extracellular vesicles alter vascular smooth muscle cell phenotype through high-mobility group box proteins by Boyer, Michael J., Kimura, Yayoi, Akiyama, Tomoko, Baggett, Ariele Y., Preston, Kyle J., Scalia, Rosario, Eguchi, Satoru, Rizzo, Victor

“…The vascular endothelium and smooth muscle form adjacent cellular layers that comprise part of the vascular wall. Each cell type can regulate the other's…”
Get full text

Quality of Life and Survival in the 2 Years After Surgery for Non–Small-Cell Lung Cancer by KENNY, Patricia M, KING, Madeleine T, VINEY, Rosalie C, BOYER, Michael J, POLLICINO, Christine A, MCLEAN, Jocelyn M, FULHAM, Michael J, MCCAUGHAN, Brian C

“…Although surgery for early-stage non-small-cell lung cancer (NSCLC) is known to have a substantial impact on health-related quality of life (HRQOL), there are…”
Get full text

Transduction Efficiency of Adenovirus Vectors in Endothelial Cells and Vascular Smooth Muscle Cells by Mokhashi, Nikita, Choi, Robert Y., Cicalese, Stephanie, Eguchi, Kunie, Boyer, Michael J., Cooper, Hannah A., Kimura, Yayoi, Akiyama, Tomoko, Scalia, Rosario, Rizzo, Victor, Eguchi, Satoru

“…Adenoviral vectors are useful tools in manipulating a gene of interest in vitro and in vivo, including in the vascular system. The transduction efficiencies of…”
Get full text

Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling by LIANGLI ZHAO, LEE, Brian Y, SUTHERLAND, Robert L, HENSHALL, Susan M, HORVATH, Lisa G, BROWN, David A, MOLLOY, Mark P, MARX, Gavin M, PAVLAKIS, Nick, BOYER, Michael J, STOCKLER, Martin R, KAPLAN, Warren, BREIT, Samuel N

“…Docetaxel chemotherapy improves symptoms and survival in men with metastatic hormone-refractory prostate cancer (HRPC). However, approximately 50% of patients…”
Get full text

Somatic mutations in salivary duct carcinoma and potential therapeutic targets by Khoo, Timothy K, Yu, Bing, Smith, Joel A, Clarke, Angus J, Luk, Peter P, Selinger, Christina I, Mahon, Kate L, Kraitsek, Spiridoula, Palme, Carsten, Boyer, Michael J, Dinger, Marcel E, Cowley, Mark J, O'Toole, Sandra A, Clark, Jonathan R, Gupta, Ruta

“…Salivary duct carcinomas (SDCa) are rare highly aggressive malignancies. Most patients die from distant metastatic disease within three years of diagnosis…”
Get full text

Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma by Yip, Po Yee, Yu, Bing, Cooper, Wendy A, Selinger, Christina I, Ng, Chiu Chin, Kennedy, Catherine W, Kohonen-Corish, Maija R J, McCaughan, Brian C, Trent, Ronald J, Boyer, Michael J, Kench, James G, Horvath, Lisa G, O'Toole, Sandra A

“…Many studies have examined specific mutations in patients with resected lung adenocarcinoma across heterogeneous stages, comprising predominantly…”
Get more information

Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial by Grimison, Peter S., Stockler, Martin R., Thomson, Damien B., Olver, Ian N., Harvey, Vernon J., Gebski, Val J., Lewis, Craig R., Levi, John A., Boyer, Michael J., Gurney, Howard, Craft, Paul, Boland, Amy L., Simes, R. John, Toner, Guy C.

“…Background The Australian and New Zealand Germ Cell Trials Group conducted a multicenter randomized phase III trial in men with good-prognosis germ cell tumors…”
Get full text

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial by Solomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven, Bauer, Todd M.

“…The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in…”
Get full text

Randomized Controlled Trial of the Role of Positron Emission Tomography in the Management of Stage I and II Non-Small-Cell Lung Cancer by VINEY, Rosalie C, BOYER, Michael J, KING, Madeleine T, KENNY, Patricia M, POLLICINO, Christine A, MCLEAN, Jocelyn M, MCCAUGHAN, Brian C, FULHAM, Michael J

“…Positron emission tomography (PET) is a costly new technology with potential to improve preoperative evaluation for patients with non-small-cell lung cancer…”
Get full text

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study by van Zandwijk, Nico, Pavlakis, Nick, Kao, Steven C, Linton, Anthony, Boyer, Michael J, Clarke, Stephen, Huynh, Yennie, Chrzanowska, Agata, Fulham, Michael J, Bailey, Dale L, Cooper, Wendy A, Kritharides, Leonard, Ridley, Lloyd, Pattison, Scott T, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Reid, Glen

“…TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss…”
Get full text

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer by Planchard, David, Boyer, Michael J, Lee, Jong-Seok, Dechaphunkul, Arunee, Cheema, Parneet K, Takahashi, Toshiaki, Gray, Jhanelle E, Tiseo, Marcello, Ramalingam, Suresh S, Todd, Alexander, McKeown, Astrid, Rukazenkov, Yuri, Ohe, Yuichiro

“…In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved…”
Get full text

Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile–Induced Abdominal Aortic Aneurysm by Kawai, Tatsuo, Takayanagi, Takehiko, Forrester, Steven J, Preston, Kyle J, Obama, Takashi, Tsuji, Toshiyuki, Kobayashi, Tomonori, Boyer, Michael J, Cooper, Hannah A, Kwok, Hang Fai, Hashimoto, Tomoki, Scalia, Rosario, Rizzo, Victor, Eguchi, Satoru

“…Angiotensin II (AngII)–activated epidermal growth factor receptor has been implicated in abdominal aortic aneurysm (AAA) development. In vascular smooth muscle…”
Get full text